ArticlemSphere2026
Durable protection against lethal Rift Valley fever hepatitis and encephalitis following low-dose ΔNSsΔNSm vaccination in mice.
Article in mSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Live-attenuated Rift Valley fever virus vaccination leads to durable, protective immunity independent of sex in C57BL/6 mice.The Journal of infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rift Valley fever virus (RVFV) is a zoonotic arbovirus that infects and causes disease in both humans and livestock. In humans, RVFV infection mostly results in febrile illness but has the potential to cause severe complications such as hepatitis and encephalitis. There are currently no licensed vaccines for human use; however, several candidates have been shown to be safe and immunogenic in pre-clinical studies. However, there remain gaps in our knowledge, including the duration of immunity and efficacy of protection from divergent disease manifestations over time. This pilot study investigated the duration of immunity following low-dose vaccination with live-attenuated RVFV ΔNSsΔNSm in two murine models with divergent RVF disease manifestations. Following percutaneous infection with wild-type (WT) RVFV, C57BL/6 mice readily succumb to fulminant hepatitis 3 to 5 days post-infection (dpi). In contrast, CC057/Unc mice from the Collaborative Cross Resource experience self-limiting liver disease and develop late-onset encephalitis. Following ΔNSsΔNSm vaccination, both humoral and cellular immunity decreased over time but were comparable between the two mouse strains at 1 and 3 months. Vaccinated mice were challenged with WT RVFV (ZH501) 6 months later, and 83% of C57BL/6 mice and 100% of CC057/Unc mice survived. Taken together, this study highlights the potential of ΔNSsΔNSm to provide durable protection against lethal RVF hepatitis and encephalitis.IMPORTANCERift Valley fever virus (RVFV) causes both morbidity and mortality in endemic areas of Africa and the Middle East; however, no vaccines are available for humans. Pre-clinical studies have investigated the safety and immunogenicity of ΔNSsΔNSm vaccine (a live-attenuated version of RVFV that has two virulence factors deleted), but the duration of immunity and protection in the context of divergent RVF disease manifestations was unknown. This pilot study demonstrated that a single, low dose of ΔNSsΔNSm provided substantial protection to mice from RVF hepatitis and encephalitis 6 months post-vaccination. These pre-clinical data could support further development of a live-attenuated vaccine based on this platform for human use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.